SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio

SSY Group Limited (HKG: 2005) announced that the Group has received drug production and registration approval from China’s National Medical Products Administration (NMPA) for Nimodipine Oral Solution (10 ml: 60 mg), classified as a Type 3 chemical drug and deemed to have passed the consistency evaluation. The product is indicated for adult patients with subarachnoid hemorrhage (SAH) resulting from ruptured intracranial cystic aneurysms, improving neurological prognosis by reducing the incidence and severity of ischemic nerve injury. This approval achieves bulk pharmaceutical–formulation integration following the NMPA registration of the Group’s nimodipine bulk drug in March 2025.

Regulatory Milestone

Drug Profile & Therapeutic Context

• Molecule: Nimodipine — a dihydropyridine calcium channel blocker with preferential cerebrovascular selectivity, originally developed by Bayer (brand name: Nimotop®).
• Formulation: Oral solution (10 ml: 60 mg) — a liquid dosage form designed for patients in critical care settings (e.g., ICU, neurosurgery wards) who may be unable to swallow solid oral dosage forms due to impaired consciousness following SAH.
• Mechanism of Action: Nimodipine selectively blocks L‑type voltage‑gated calcium channels in cerebral vasculature, preventing cerebral vasospasm — the primary cause of delayed cerebral ischemia (DCI) and secondary neurological injury following SAH. By maintaining cerebral blood flow, nimodipine reduces the incidence and severity of ischemic nerve damage.
• Clinical Guideline Status: Nimodipine is the only pharmacological agent with Level 1A evidence for the prevention of vasospasm‑related neurological deficits following aneurysmal SAH, and is included in all major international and Chinese clinical guidelines for SAH management (AHA/ASA, ESO, Chinese Stroke Society).
• Standard Dosing: 60 mg (10 ml) every 4 hours for 21 consecutive days post‑SAH — a well‑established regimen with decades of clinical use.

Strategic Significance – Bulk Drug‑to‑Formulation Integration

• Vertical Integration Achieved: The nimodipine oral solution approval completes the API‑to‑formulation value chain within the SSY Group — the bulk drug (approved March 2025) now feeds directly into the finished oral solution product, enabling cost‑efficient manufacturing, supply chain control, and margin capture across the entire production process.
• Consistency Evaluation Advantage: Passing the consistency evaluation confirms that the Group’s nimodipine oral solution is therapeutically equivalent to the originator product, enabling participation in volume‑based procurement (VBP) tenders and hospital formulary listings on equal footing with branded competitors.

Market Impact & Outlook

• China SAH Epidemiology: Subarachnoid hemorrhage accounts for approximately ~5–10% of all strokes in China, with an estimated ~100,000+ annual cases of aneurysmal SAH. Given China’s aging population and high prevalence of cerebrovascular risk factors, the SAH treatment market remains a stable, high‑acuity demand segment.
• ICU/Critical Care Channel: Nimodipine oral solution is a standard‑of‑care, guideline‑mandated product in the management of aneurysmal SAH — administered in neurosurgery ICUs and stroke centers across China’s hospital system. The oral solution formulation is particularly suited for this channel, as SAH patients frequently require nasogastric or orogastric tube administration due to impaired consciousness.
• VBP Participation: As a Type 3 chemical drug that has passed the consistency evaluation, SSY’s nimodipine oral solution is eligible for national and provincial volume‑based procurement (VBP) programs — China’s primary mechanism for generic drug reimbursement and hospital market access. VBP inclusion could drive rapid volume uptake at the cost of pricing compression.
• Cerebrovascular Portfolio Enrichment: The approval adds nimodipine oral solution to SSY Group’s growing portfolio in cardiovascular, cerebrovascular, and critical neurological fields — therapeutic areas aligned with China’s highest‑burden disease categories and the Group’s core strategic focus.
• Competitive Landscape: Nimodipine oral solution is a well‑established generic product with multiple domestic manufacturers in China. SSY’s competitive positioning will depend on manufacturing cost efficiency (enhanced by in‑house API supply), VBP pricing competitiveness, and hospital channel coverage — areas where the Group’s established commercial infrastructure provides an advantage.
• Portfolio Pipeline Implications: The successful bulk drug‑to‑formulation integration with nimodipine may serve as a replicable model for other API assets in SSY Group’s pipeline, potentially accelerating the development and registration of additional finished dosage forms across the Group’s therapeutic focus areas.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercial potential of nimodipine oral solution, VBP participation, market access dynamics, and portfolio development plans. Actual results may differ materially due to risks including VBP pricing outcomes, competitive dynamics in the generic nimodipine market, hospital formulary listing timelines, manufacturing scale‑up, reimbursement policy changes, and the inherent uncertainties of pharmaceutical commercialization. This announcement is a voluntary disclosure by SSY Group Limited. Investors are advised to exercise caution.-Fineline Info & Tech